KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.90

Comparing the Recurrence Patterns of Reduced-Margins vs. RTOG-Protocol in Adjuvant Chemoradiation of High-Grade Gliomas: A Multicenter, Open-Label, Randomized Controlled Trial.

Kazem Anvari, Sseyed Alireza Javadinia, Danial Fazilatpanah, Habibollah Esmaily, Seyed Amir Aledavood, Soudabe Shahidsales, Babak Ganjeifar, Mahdiye Dayani, Parisa Rabiei

Asian Pac J Cancer Prev 27(6) 2005-2013

PMID42345146
PMCID-
DOI10.31557/APJCP.2026.27.6.2005
发表日期2026-06-25
入排依据:The study is a Phase III randomized controlled trial with a primary time-to-event endpoint (PFS) for a human malignant neoplasm (high-grade glioma). However, the randomized intervention is a comparison of radiotherapy target volume margins (reduced-margin vs. standard RTOG-protocol), not a drug-containing intervention. The abstract does not describe a drug-containing arm as part of the randomized comparison; 'adjuvant chemoradiation' in the title likely refers to the overall treatment context, not the experimental variable being tested.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Radiotherapy following maximal-safe resection is a cornerstone of treatment for high-grade gliomas (HGGs). However, the optimal clinical target volume (CTV) margin remains controversial. This study aimed to evaluate the safety, efficacy, and recurrence patterns associated with a reduced CTV margin in patients with HGGs, compared to standard RTOG-based planning. METHODS: In this multicenter, phase III randomized clinical trial, patients aged 18-75 years with newly diagnosed WHO-grade 3 or 4 gliomas were randomly assigned to receive adjuvant radiotherapy with either a standard 2-cm clinical target volume (CTV) margin (control group) or a reduced 1-cm margin (intervention group). The primary endpoint was progression-free survival (PFS), while the secondary endpoints included overall survival (OS) and patterns of recurrence. RESULTS: A total of 258 patients were enrolled, of whom 75.6% had grade 4 gliomas. After a median follow-up of 14.5 months, median PFS was 15 ± 1.25 months in the intervention group but it was 19 ± 2.71 months in the control group (hazard ratio [HR] = 1.32; 95% CI, 0.93-1.87; p = 0.121). Median OS was 22.0 ± 2.98 months in the intervention group, while it was not reached in the control group (HR = 1.52; 95% CI, 0.99-2.33; p = 0.057). Imaging progression occurred in 35% of patients in the intervention group and 32.2% in the control group (p = 0.637). In-field recurrence was the predominant pattern in both groups (84% vs. 83.8%; p = 0.829), with no significant increase in marginal or out-of-field failures associated with margin reduction. CONCLUSION: Reducing the clinical target volume (CTV) margin from 2 cm to 1 cm in the adjuvant radiotherapy of high-grade gliomas did not significantly affect progression-free survival (PFS), overall survival (OS), or recurrence patterns. These findings support the feasibility and safety of margin reduction, even in settings where three-dimensional conformal radiotherapy (3D-CRT) is the primary technique.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。